CTOs on the Move

BioShield Technologies

www.bioshield.com

 
BioShield Technologies is a Norcross, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.bioshield.com
  • 4405 International Blvd Ste b109
    Norcross, GA USA 30093
  • Phone: 770.925.4302

Executives

Name Title Contact Details

Similar Companies

Joslin Diabetes Center

Joslin Diabetes Center is world-renowned for its deep expertise in diabetes treatment and research. Joslin is dedicated to finding a cure for diabetes and ensuring that people with diabetes live long, healthy lives. We develop and disseminate innovative patient therapies and scientific discoveries throughout the world. Joslin is an independent, non-profit institution affiliated with Harvard Medical School, and one of only 11 NIH-designated Diabetes Research Centers in the U.S.

Hamilton

The leader in liquid handling equipment and laboratory automation technology, Hamilton Robotics is recognized for advancing life science and biotechnology industries with products that offer reliability, performance and flexibility. Hamilton is the ind...

BioEnterprise Corporation

BioEnterprise Corporation is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ValGenesis

As a pioneer in the development of automated validation software solutions, ValGenesis leads the way with a unique paperless validation process that tracks the validation status of any GxP system in real time. With years of development and refinement in place, ValGenesis is the first to offer users real-time paperless validation via electronic execution thereby minimizing ineffectiveness and maximizing efficiency. ValGenesis automates and manages the validation life cycle and provides real time validation status of any system corporate wide.

Capstan Therapeutics

Capstan Therapeutics is a biotechnology company dedicated to advancing in vivo cell reprogramming. The core platform technology comprises proprietary targeted lipid nanoparticles conjugated with a recombinant protein binder such as monoclonal antibodies (tLNPs) designed to deliver payloads, including mRNA or gene editing tools, that can reprogram specific cell types in vivo. The platform technology has the potential to generate transformative therapies with applications across a broad range of disease areas, including oncology, autoimmune disorders, fibrosis, and monogenic blood disorders.